Prevalence and factors associated with the intention to vaccinate against COVID-19 in Peru


  • Percy Herrera-Añazco Universidad Privada San Juan Bautista. Lima, Perú.Red Internacional en Salud Colectiva y Salud Intercultural. Ciudad de México, México.Instituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud. Lima, Perú.Médico nefrólogo
  • Ángela Uyen-Cateriano Médicos Sin Fronteras. Política Sanitaria. Bruselas, Bélgica.magíster en Administración de Empresas de Salud y magíster en Relaciones Internacionales
  • Diego Urrunaga-Pastor Universidad Científica del Sur. Lima, Perú.médico cirujano
  • Guido Bendezu-Quispe Red Internacional en Salud Colectiva y Salud Intercultural. Ciudad de México, México.Centro de Investigación Epidemiológica en Salud Global, Universidad Privada Norbert Wiener. Lima, Perú.magíster en Informática Biomédica
  • Carlos J. Toro-Huamanchumo Facultad de Medicina Humana, Universidad de San Martín de Porres. Chiclayo, Perú.Unidad de Investigación Multidisciplinaria, Clínica Avendaño. Lima, Perú.médico epidemiólogo
  • Alfonso J. RodrÍguez-Morales Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas. Pereira, Colombia.Asociación Colombiana de Infectología. Bogotá, Colombia.médico tropicalista e investigador sénior
  • Adrian V. Hernández University of Connecticut. Storrs, Connecticut, Estados Unidos.Unidad de Revisiones Sistemáticas y Meta-análisis, Guías de Práctica Clínica y Evaluaciones Tecnológicas Sanitarias. Universidad San Ignacio de Loyola, Lima, Perú.doctor en Epidemiología Clínica
  • Vicente A. Benites-Zapata Red Internacional en Salud Colectiva y Salud Intercultural. Ciudad de México, México.Unidad para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola. Lima, Perú.magíster en Investigación Epidemiológica



COVID-19, SARS-Co-V2, COVID-19 Vaccines, Vaccination, Vaccination Refusal, Peru


Objectives: To estimate the prevalence and factors associated with COVID-19 vaccination intention (VI) in Peru. Materials and methods: Analytical cross-sectional study using the survey conducted by the University of Maryland, USA, on Facebook. The dependent variable is VI. Crude and adjusted prevalence ratios (PR) were calculated, with their 95% confidence intervals (95%CI) using generalized linear models of the Poisson family, to evaluate the association of sociodemographic variables, compliance with community mitigation strategies, symptoms of COVID-19, mental health and acceptance of vaccination before the recommendation (AVR) by various actors and health authorities, with the ITV. Results: Data from 17,162 adults were analyzed. The overall prevalence of VI was 74.9%. A lower prevalence of VI was associated with the female sex (PR=0.95; 95%CI:0.94-0.97), living in a town (PR=0.95; 95%CI:0.91-0.99) or village or other rural area (PR=0.90; 95%CI:0.86-0.93) and the AVR of politicians (PR=0.89; 95%CI:0.87-0.92). Conversely, having COVID-19 symptoms (PR=1.06; 95%CI:1.03-1.09), economic insecurity (PR=1.04; 95%CI:1.01-1.06), fears of becoming seriously ill or that a family member becomes seriously ill from COVID-19 (PR=1.49; 95%CI:1.36-1.64) and the AVR of family and friends (PR=1.10; 95%CI: 1.08-1.12), healthcare workers (PR=1.29; 95%CI: 1.26-1.32), World Health Organization (PR=1.34; 95%CI: 1.29-1.40) and government officials (PR=1.18; 95%CI: 1.15-1.22) was associated with a higher prevalence of VI. Conclusions: Three-quarters of the respondents had VI. There are potentially modifiable factors that could improve vaccine acceptance.


Download data is not yet available.



How to Cite

Herrera-Añazco P, Uyen-Cateriano Ángela, Urrunaga-Pastor D, Bendezu-Quispe G, Toro-Huamanchumo CJ, RodrÍguez-Morales AJ, Hernández AV, Benites-Zapata VA. Prevalence and factors associated with the intention to vaccinate against COVID-19 in Peru. Rev Peru Med Exp Salud Publica [nternet]. 2021 Aug. 26 [cited 2023 Sep. 25];38(3):381-90. vailable from:



Original Article

Most read articles by the same author(s)

1 2 3 4 5 > >>